Effects of AGI-1067 and probucol after percutaneous coronary interventions
- PMID:12566365
- DOI: 10.1161/01.cir.0000047525.58618.3c
Effects of AGI-1067 and probucol after percutaneous coronary interventions
Abstract
Background: AGI-1067, a metabolically stable modification of probucol, is an equipotent antioxidant to probucol but is pharmacologically distinct. In a multicenter trial, we studied whether AGI-1067 reduces restenosis assessed by intravascular ultrasound (IVUS) after percutaneous coronary intervention (PCI) compared with placebo and probucol used as a positive control.
Methods and results: Two weeks before PCI, 305 patients were randomly assigned to 1 of 5 treatment groups: placebo, probucol 500 mg BID, or AGI-1067 70, 140, or 280 mg once daily. Patients were treated for 2 weeks before and 4 weeks after PCI. Baseline and 6-month follow-up IVUS were interpreted by a blinded core laboratory. Stents were used in 85% of patients. Luminal area at the PCI site at follow-up was 2.66+/-1.58 mm2 for placebo, 3.69+/-2.69 mm2 for probucol, 2.75+/-1.76 mm2 for AGI-1067 70 mg, 3.17+/-2.26 mm2 for AGI-1067 140 mg, and 3.36+/-2.12 mm2 for AGI-1067 280 mg (P=0.02 for the dose-response relationship; P< or =0.05 for AGI-1067 280 mg and probucol versus placebo). There was a mean narrowing of 5.3 mm3 of reference segment lumen in the placebo group and an enlargement in the AGI-1067 140- and 280-mg groups at follow-up (P=0.05 for 140 mg). An increase in QTc interval >60 ms occurred in 4.8% of placebo patients, 17.4% of probucol patients, and 4.8%, 2.4%, and 2.5% of patients in the AGI-1067 groups (P=0.02).
Conclusions: AGI-1067 and probucol reduce restenosis after PCI. In contrast to probucol, AGI-1067 did not cause prolongation of the QTc interval and improved lumen dimensions of reference segments, suggestive of a direct effect on atherosclerosis.
Similar articles
- Clinical results with AGI-1067: a novel antioxidant vascular protectant.Tardif JC.Tardif JC.Am J Cardiol. 2003 Feb 6;91(3A):41A-49A. doi: 10.1016/s0002-9149(02)03149-1.Am J Cardiol. 2003.PMID:12645643Review.
- Prevention of restenosis with antioxidants: mechanisms and implications.Tardif JC, Grégoire J, L'Allier PL.Tardif JC, et al.Am J Cardiovasc Drugs. 2002;2(5):323-34. doi: 10.2165/00129784-200202050-00005.Am J Cardiovasc Drugs. 2002.PMID:14727962Review.
- Pharmacologic prevention of both restenosis and atherosclerosis progression: AGI-1067, probucol, statins, folic acid and other therapies.Tardif JC, Grégoire J, Lavoie MA, L'Allier PL.Tardif JC, et al.Curr Opin Lipidol. 2003 Dec;14(6):615-20. doi: 10.1097/00041433-200312000-00010.Curr Opin Lipidol. 2003.PMID:14624139Review.
- Experimental and clinical studies show that the probucol derivative AGI-1067 prevents vascular growth.Doggrell SA.Doggrell SA.Expert Opin Investig Drugs. 2003 Nov;12(11):1855-9. doi: 10.1517/13543784.12.11.1855.Expert Opin Investig Drugs. 2003.PMID:14585060Review.
- Impact of residual plaque burden after balloon angioplasty in the MultiVitamins and Probucol (MVP) trial.Tardif JC, Côté G, Lespérance J, Gosselin G, Joyal M, de Guise P, Bilodeau L, Doucet S, Harel F, Couturier A, Gallo R, Grégoire J.Tardif JC, et al.Can J Cardiol. 2001 Jan;17(1):49-55.Can J Cardiol. 2001.PMID:11173314Clinical Trial.
Cited by
- Intravascular ultrasound assessment of atherosclerosis.Guédès A, Tardif JC.Guédès A, et al.Curr Atheroscler Rep. 2004 May;6(3):219-24. doi: 10.1007/s11883-004-0035-4.Curr Atheroscler Rep. 2004.PMID:15068747Review.
- The role of intravascular ultrasound in the determination of progression and regression of coronary artery disease.Kaneda H, Terashima M, Yamaguchi H.Kaneda H, et al.Curr Atheroscler Rep. 2012 Apr;14(2):175-85. doi: 10.1007/s11883-012-0234-3.Curr Atheroscler Rep. 2012.PMID:22318481Review.
- AGI-1067, a novel antioxidant and anti-inflammatory agent, enhances insulin release and protects mouse islets.Crim WS, Wu R, Carter JD, Cole BK, Trace AP, Mirmira RG, Kunsch C, Nadler JL, Nunemaker CS.Crim WS, et al.Mol Cell Endocrinol. 2010 Jul 29;323(2):246-55. doi: 10.1016/j.mce.2010.02.041. Epub 2010 Mar 6.Mol Cell Endocrinol. 2010.PMID:20211684Free PMC article.
- Pharmacological basis of different targets for the treatment of atherosclerosis.Saini HK, Xu YJ, Arneja AS, Tappia PS, Dhalla NS.Saini HK, et al.J Cell Mol Med. 2005 Oct-Dec;9(4):818-39. doi: 10.1111/j.1582-4934.2005.tb00382.x.J Cell Mol Med. 2005.PMID:16364193Free PMC article.Review.
- Safety and Efficacy of Post-Dilation in Percutaneous Coronary Intervention Using Polymer-Free Ultrathin Strut Sirolimus-Probucol Coated Drug-Eluting Stents.Shin Y, Won Y, Yang T, Kim J, Lee J, Seo J, Jang AY, Kim M, Oh PC, Lee K, Kang WC, Han SH, Suh SY.Shin Y, et al.Medicina (Kaunas). 2023 Sep 12;59(9):1649. doi: 10.3390/medicina59091649.Medicina (Kaunas). 2023.PMID:37763768Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous